What is OSR?
If you have spent any real time in mercury detox circles, you have heard about OSR, sometimes called NBMI or emeramide. It is one of those compounds that refuses to stay obscure, not because it is trendy, but because people keep talking about their experiences with it.
OSR is a fat-soluble metal-binding compound originally developed for serious metal exposure scenarios. Unlike water-soluble chelators, it is often discussed in the context of deep tissue and neurological mercury, which is why it attracts attention from people who feel stuck after years of conventional approaches.
It is also not part of mainstream clinical practice, and that matters.
What does the actual research show?
This is worth stating plainly, because the article's own framing is that the OSR conversation happens off the record. Some of it does. But there is more formal research than most people in those conversations realise.
NBMI has been through registered clinical trials sponsored by EmeraMed:
| Trial | Indication | Phase | Status |
|---|---|---|---|
| NCT03123692 | COPD | Phase 2 | Completed |
| NCT04184063 | Atypical Parkinsonism (PSP/MSA) | Phase 2a | Completed |
| NCT04092205 | Beta thalassaemia, iron chelation | Phase 2a | Completed |
| NCT04183595 | Mercury toxicity, Colombia | — | Status unknown |
A 2023 post hoc analysis in BioMetals reported reductions in plasma and urine mercury following NBMI therapy in a randomised human trial.
What this does and does not mean. It means NBMI is a real compound with a real research programme, not a rumour. It does not mean it is approved, proven, or safe for unsupervised use. Phase 2 establishes preliminary safety and signals of effect. It is not the finish line, and several of these trials completed years ago without leading to approval.
Read that as reason for informed interest, not reassurance.
The reality no one likes to say out loud
OSR lives in a grey zone. Not because mercury toxicity is theoretical, but because regulation, research timelines, and real-world demand do not move in sync.
As a result, most day-to-day discussion about OSR does not happen in journals or clinics. It happens peer to peer. People compare notes. They notice patterns. They talk about what went well, what did not, and what they wish they had done first.
That does not make OSR a miracle. It does mean the conversation exists, whether practitioners acknowledge it or not.
What patterns show up repeatedly?
Across responsible discussions, a few consistent themes surface:
- OSR is not a shortcut for skipping foundational work
- Experiences appear strongly influenced by mineral status, nervous system stability, and elimination capacity
- People who rush or stack it impulsively often report problems
- People who approach it after stabilising minerals and detox pathways tend to describe smoother experiences
In other words, OSR does not override biology. It seems to amplify the terrain you already have.
That is the same principle running through this entire series.
A caution about that evidence. Peer reports are pattern, not proof. Online groups systematically over-represent people who had notable experiences and under-represent those who quietly stopped, and nobody is tracking the people who got worse and left.
Where does OSR fit in the bigger picture?
One hierarchy has stayed consistent throughout this series:
- Reduce exposure, especially dental mercury
- Stabilise the terrain: minerals, thyroid, nerves, bile, kidneys, bowels
- Mobilise carefully, with respect for timing and capacity
OSR tends to attract people who are ready for step three, or who wish step three could fix what steps one and two did not fully address.
Sometimes that curiosity is reasonable. Sometimes it is desperation.
Knowing the difference matters.
If you are curious, be curious responsibly
This page does not direct anyone to use or avoid OSR; excluding it from the discussion does not support informed decisions.
If you want to understand how people are actually discussing OSR, including cautions, long-term experiences, and what not to do, most of that information lives in private discussion groups rather than polished blogs.
That is not a recommendation. It is context.
One active space is The Mercury Heavy Metal Chelation group on Facebook. As with any open forum, read widely, weigh patterns over anecdotes, and make informed choices that fit your own situation.
Bottom line
OSR, NBMI, emeramide is part of the modern mercury conversation because people are still looking for answers, especially around neurological symptoms and long-standing exposure.
Whether someone explores it or not, the same truth applies:
Mineral stability, detox capacity, and patience determine outcomes far more than the name of the chelator.
Skip those and no compound saves you. Respect them and everything works better.
What this article does not tell you
- OSR is not approved for human use in the United States, the EU, or elsewhere. It is investigational.
- This is not a dosing guide, and deliberately so. Dosing information for an unapproved compound does not belong on a public page.
- Sourcing is unregulated. Material sold as OSR is not subject to pharmaceutical manufacturing standards, and there is no way for a buyer to verify what is in it without independent testing.
- Long-term safety data does not exist, because the trials that would produce it have not been done.
- Peer reports are not evidence of safety. They are a description of what some people experienced, filtered by who chose to report.
- Anyone considering this needs medical supervision, and should tell their physician regardless of what the physician thinks of it.
- Testing shows patterns, not diagnoses.
References and further reading
- Geier, D.A. and Geier, M.R. Reductions in plasma and urine mercury concentrations following NBMI therapy: a post hoc analysis of data from a randomized human clinical trial. BioMetals, 2023.
- ClinicalTrials.gov: NCT03123692, NCT04184063, NCT04092205, NCT04183595. EmeraMed.
- Literature on NBMI affinity for mercury, cadmium and lead, including preclinical models.
- Cutler, Andrew, PhD and Rebecca Rust Lee. The Mercury Detoxification Manual.
- VIGEO Health Medical Disclaimer
Series navigation
← Part 9: How often should you dose during chelation? Series complete. Back to the Chelation Education Series
Questions and Answers
Q: What is OSR (NBMI / emeramide)? A: A fat-soluble metal-binding compound originally developed for serious metal exposure. Unlike water-soluble chelators it can cross lipid membranes, which is why it is discussed in the context of deep tissue and neurological mercury. It is not an approved medication and is not part of mainstream clinical practice.
Q: Is OSR safe? A: There is not enough evidence to answer that. NBMI has completed several registered Phase 2 trials sponsored by EmeraMed, covering COPD, atypical Parkinsonism, and iron chelation in beta thalassaemia, and a 2023 post hoc analysis reported reductions in plasma and urine mercury. None of this has led to approval, long-term safety data does not exist, and material sold as OSR is not manufactured to pharmaceutical standards.
Q: Has NBMI been studied in clinical trials? A: Yes. Registered Phase 2 trials sponsored by EmeraMed include NCT03123692 in COPD, NCT04184063 in progressive supranuclear palsy and multiple system atrophy, and NCT04092205 in beta thalassaemia. A trial in mercury-exposed subjects in Colombia, NCT04183595, has an unknown current status. Phase 2 establishes preliminary safety and signals of effect rather than proving efficacy.
Q: Where does OSR fit in a chelation approach? A: After the foundations, not instead of them. The consistent hierarchy is reducing exposure first, particularly dental mercury, then stabilising minerals, thyroid, nerves, bile, kidneys and bowels, and only then mobilising metals with attention to timing and capacity. Reports suggest OSR amplifies existing terrain rather than compensating for poor terrain.